Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
about
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disordersPotentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusIntranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the artInsulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndromeFood for thought: the role of appetitive peptides in age-related cognitive declineTherapeutic targets of brain insulin resistance in sporadic Alzheimer's diseaseGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideBrain insulin resistance and deficiency as therapeutic targets in Alzheimer's diseaseDiabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studiesGIP and GLP-1, the two incretin hormones: Similarities and differencesCSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's DiseaseGlucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities.Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models.GLP-1 based therapeutics: simultaneously combating T2DM and obesity.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.The GLP-1 Receptor Agonist Exendin-4 and Diazepam Differentially Regulate GABAA Receptor-Mediated Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic ratsAn anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's diseaseIn Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.The functional state of hormone-sensitive adenylyl cyclase signaling system in diabetes mellitusBrain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.Gut to Brain Dysbiosis: Mechanisms Linking Western Diet Consumption, the Microbiome, and Cognitive Impairment.Insulin dysfunction and allostatic load in bipolar disorder.Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.A review: treatment of Alzheimer's disease discovered in repurposed agents.Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models.Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.GLP-1: benefits beyond pancreas.Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.Liraglutide for Type 2 diabetes and obesity: a 2015 update.
P2860
Q24562763-1A5732E3-2B20-4EA2-966F-429F06A9785AQ26774021-5CF7378E-8928-4438-B31F-85C249E27FCAQ26830845-C2C7E7E8-AC3E-47B6-9808-7B90E7A92C9EQ27008997-E5AF0D47-E3E7-433B-93BE-5A666DF6B659Q27009988-01BCEC42-7E29-41EF-BDDD-20C41752EBBBQ27021700-823D0EAD-C30C-4D9E-8549-663C073BAFB6Q28081671-9E0B52FC-0875-4380-860F-EAD7916A0147Q28259585-833070F3-182A-4873-8CF3-7D573872BE22Q28538916-6C148138-99D9-4B79-8DD2-898214DFC461Q33609502-A0AA3CA5-C4BE-4ECD-AD0B-E2FF8E737819Q33896118-3E2A9AC1-FD6D-43BB-B22F-6F7CD625BDC5Q34379379-7A8972D7-2742-4642-AA4A-B4D15ECC4B96Q34639384-CFA6DC54-6BA4-4EB9-9839-374C4D8C56D1Q34745109-E963304A-D936-441D-B672-94B0C18BF432Q35070673-423FA929-A8C6-476D-862A-6BAC20E3C5F7Q35106896-B461964F-A4D1-460A-9AE9-62AE86740804Q35200252-BE217F4A-3EF3-4375-9DB9-09490DB672FEQ35285238-E8175ECC-FBCC-413E-BBEE-61CC9BB0DD8AQ35619029-9D4EC964-7D63-4B95-A881-F01C043B5A54Q35690970-A47877CF-CBB2-49DC-AAEC-0D7134195047Q35709472-0E2512CC-7D0C-4A67-98F3-6FCCBBC4D804Q35858008-2143EE17-7E95-44FE-8964-DEC718E7FF97Q35997824-EC3E6DB1-AE41-4FE5-A663-4A15327AFE84Q36928283-0898787B-D458-49EA-B08A-3D0D55D7090DQ37245273-60D77DC7-BC8E-46B8-9B8B-484E44BE1F6DQ37474214-09B07802-EB39-47CE-9144-3D4E13A85EF1Q37516654-862DC1BF-8A83-4EAD-A25F-7712FFD2FD15Q37611785-C574ADB3-88A7-428B-89E8-D925A9F358E1Q37896630-1D7A17C5-6037-4A94-B2BC-B5AA0E961D6FQ37900307-4AC144EC-38CD-4ECB-8210-03566A8812D2Q37992259-46CF73C9-92A3-467B-84DE-84FC6FC2099AQ38039489-150D68FD-D9C5-4608-942A-9D9A08B8E556Q38073138-B2C7582F-4A1B-4F35-A28D-63AB4C0C8DC0Q38182056-B0138195-275F-47E8-A15D-EC40A85A2CF4Q38197368-2F54C81A-C3E6-4254-BD17-EFE9CF6D7891Q38225930-B6F6A6E7-7C81-424F-8DD1-896CB96FD246Q38238288-60497057-3B29-4C23-9D08-13FCE55D19B3Q38324750-1FFACF30-2B4D-44FC-8A13-B2E9F83A062CQ38337206-15BF2699-7BB4-4F3D-A5D7-C8EB16067446Q38536672-0B5C2CF7-7465-4E81-9EDF-F5E764BC0922
P2860
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@en
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@nl
type
label
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@en
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@nl
prefLabel
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@en
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@nl
P1476
Glucagon-like peptide-1 analog ...... betes and Alzheimer's disease.
@en
P2093
Patrick Harriott
Paula L McClean
P304
P356
10.1016/J.EJPHAR.2009.12.023
P407
P577
2009-12-24T00:00:00Z